Abstract:BackgroundAlzheimer's disease (AD) is a fatal disease that threatens the quality of life of an aging population at a global scale. Various hypotheses on the etiology of AD have been developed over the years to guide efforts in search of therapeutic strategies.Main bodyIn this review, we focus on four AD hypotheses currently relevant to AD onset: the prevailing amyloid cascade hypothesis, the well-recognized tau hypothesis, the increasingly popular pathogen (viral infection) hypothesis, and the infection-related antimicrobial protection hypothesis. In briefly reviewing the main evidence supporting each hypothesis and discussing the questions that need to be addressed, we hope to gain a better understanding of the complicated multi-layered interactions in potential causal and/or risk factors in AD pathogenesis. As a defining feature of AD, the existence of amyloid deposits is likely fundamental to AD onset but is insufficient to wholly reproduce many complexities of the disorder. A similar belief is currently also applied to hyperphosphorylated tau aggregates within neurons, where tau has been postulated to drive neurodegeneration in the presence of pre-existing A plaques in the brain. Although infection of the central nerve system by pathogens such as viruses may increase AD risk, it is yet to be determined whether this phenomenon is applicable to all cases of sporadic AD and whether it is a primary trigger for AD onset. Lastly, the antimicrobial protection hypothesis provides insight into a potential physiological role for A peptides, but how A/microbial interactions affect AD pathogenesis during aging awaits further validation. Nevertheless, this hypothesis cautions potential adverse effects in A-targeting therapies by hindering potential roles for A in anti-viral protection.ConclusionAD is a multi-factor complex disorder, which likely requires a combinatorial therapeutic approach to successfully slow or reduce symptomatic memory decline. A better understanding of how various causal and/or risk factors affecting disease onset and progression will enhance the likelihood of conceiving effective treatment paradigms, which may involve personalized treatment strategies for individual patients at varying stages of disease progression.

Advances in the Pathogenesis of Alzheimer's Disease: a Re-Evaluation of Amyloid Cascade Hypothesis.

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration

New Insights Into the Pathogenesis of Alzheimer's Disease

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Advances in the Mechanism and Pharmacotherapies of Alzheimer's Disease

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Pathological mechanisms and therapeutic strategies for Alzheimer’s disease

Progress in pathogenesis and treatment of Alzheimer's disease

Advances In Recent Patent And Clinical Trial Drug Development For Alzheimer'S Disease

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis

Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease

Advances in the β-amyloid precursor protein of Alzheimer's disease

Sequence of Molecular Events in the Development of Alzheimer's Disease: Cascade Interactions from Beta-Amyloid to Other Involved Proteins

Alzheimer's Disease: an Axonal Injury Disease?

Current Advances in the Treatment of Alzheimer's Disease: Focused on Considerations Targeting Aβ and Tau

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

Alzheimer’s Disease: an Axonal Injury Disease?

A review of the roles of pathogens in Alzheimer's disease

Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses